Juno: Jury awards BMS subsidiary $752M in CAR-T patent infringement suit
A federal jury in California found that Kite Pharma - now part of Gilead Sciences - violated a patent from Memorial Sloan Kettering Cancer Center and licensed to BMS' Juno Therapeutics in developing the CAR-T therapy Yescarta, approved in 2017.
Read full article »
CEO
Juno is a biopharmaceutical company that researches and develops cellular immunotherapies for the treatment of cancer.
Read more